Sargramostim
Leukocyte Growth Factor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: BI 61.012, leukine, sargramostim (genetical recombination)
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Sargramostim is a drug in the Leukocyte Growth Factor class catalogued in DrugCentral. It was first approved by the FDA in 1991. DrugCentral lists 1 molecular target, including CSF2RA|CSF2RB. Recorded indications include Chemotherapy-induced neutropenia.
- Drug class: Leukocyte Growth Factor.
- Molecular targets: CSF2RA|CSF2RB (1 listed in DrugCentral).
- Indications: Chemotherapy-induced neutropenia.
- ATC code: L03AA09 (Colony stimulating factors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Chemotherapy-induced neutropenia
Mechanism & targets
| Established pharmacologic class | Leukocyte Growth Factor |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Granulocyte macrophage colony-stimulating factor receptor | CSF2RA|CSF2RB | agonist | Kd 8.30 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1991-03-05 | FDA | — | BERLEX LABS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L03AA09 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Device related bacteraemia | 87.0 |
| Pyrexia | 78.1 |
| Hypotension | 67.1 |
| Device related infection | 50.9 |
| Chills | 48.9 |
| Bone pain | 39.0 |
| Pain | 35.8 |
| Injection site reaction | 35.4 |
| Hyperhidrosis | 33.7 |
| Syncope | 32.0 |
| Device occlusion | 26.7 |
| White blood cell count increased | 26.4 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 123774-72-1 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Sargramostim used for?
DrugCentral lists the following indications for Sargramostim: Chemotherapy-induced neutropenia.
How does Sargramostim work?
Its molecular targets in DrugCentral include CSF2RA|CSF2RB (agonist).
When was Sargramostim first approved?
Sargramostim was first approved by the FDA in 1991.
What drug class does Sargramostim belong to?
Sargramostim is in the Leukocyte Growth Factor class.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5025 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201670 — compound record and bioactivity
- DrugBank DB00020 — drug record
- FDA UNII 5TAA004E22 — substance identity
- DailyMed: FDA labels for Sargramostim — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.